

6 September 2016

Pathophysiology of Cardiogenic Shock & Heart Failure



เอกราช อริยะชัยพาณิชย์

Heart Failure and Transplant Cardiology

aekarach.a@chula.ac.th

Agenda


- Cardiac physiology
- Pathophysiology of shock
- Pathophysiology of heart failure





<http://fullpulse.weebly.com/conversation>

Cardiovascular system


1. What is the heart ?
2. What is the function of the heart ?



Google  

[Web](#) [Images](#) [Videos](#) [News](#) [More ▾](#) [Search tools](#)

About 687,000,000 results (0.50 seconds)

heart
/hɑːt/ 

noun

1. a hollow muscular organ that pumps the blood through the circulatory system by rhythmic contraction and dilation. In vertebrates there may be up to four chambers (as in humans), with two atria and two ventricles.
synonyms: informal ticker
"my heart stopped beating"

The cardiovascular system


Cardiac output (CO)



- The blood flow thru the heart in 1 minute
- L/min
- **Stroke volume x Heart rate**

Intrinsic heart mechanics properties


- Preload // Contractility // Afterload

What is preload ?







Frank-Starling Mechanism



Preload: Cellular level




Preload in clinical

A “load” to the contractile unit before contraction



- A load =

Molecular	z-z line contractile protein
Cellular	myocardial cell length
Heart	Wall stress
	LV end diastolic pressure --- LVEDP
	LV end diastolic volume --- LV size
	RA pressure --- JVP
	Volume status


What is afterload ?



Afterload




1



2




3



4


Afterload



Afterload in Clinical

A “load” that the heart has to contract against

- Systolic blood pressure
- Systolic vascular resistant
- vaso-constriction



What is shock ?

What is shock ?

“The clinical syndrome from various causes that result in damages due to **inadequate global tissue perfusion.**”

- Inadequate O2 delivery
- Usually have hypotension (MAP < 60 mmHg)

Lead to a **vicious cycle**, due to

- Organ protective mechanism
- Cellular dysfunction → functional and structural change.

multiple organ failure and death.

Adapt from harrison principles of internal medicine 18th edition

HYPOTENSION ≠ SHOCK

Hypoperfusion: Cellular responses

- ATP depletion
- Aerobic to anaerobic
- Abnormal membrane function
- Cell dysfunction, swelling, death
- Inflammatory response
- Hematologic response

Hypoperfusion: Autonomic responses

- Sympathetic nervous system
 - Baroreceptor, adrenal gland
 - NE, epinephrine, dopamine, and cortisol release
 - Vasoconstriction, ↑ HR, ↑ contractility, ↑ BP
- Renin-angiotensin-aldosterone system
 - Water and Na absorption, vasoconstriction
 - ↑ blood volume and ↑ BP
- ADH (vasopressin), cortisol,

Multi organ dysfunction

- Renal failure
 - Acute kidney injury
- Liver failure
 - Ischemic hepatitis, shock liver
- DIC
- Respiratory distress or failure
- Cardiac depression





Figure 270-1 Shock-induced vicious cycle.

How many type of shock are there ?

B Types of shock



NEJM 2013

Type of shock

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic				
Cardiogenic				
Distributive				
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Type of shock

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic	↓			
Cardiogenic		↓		
Distributive			↓	
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Type of shock

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic	↓	~↑	↑	Blood or fluid loss (internal, external)
Cardiogenic	↑	↓	↑	Acute MI, acute HF Arrhythmia, cardiac tamponade pulmonary emboli
Distributive	~↓	↑↓	↓	Septic, anaphylaxis, inflammation, toxin
Other type of shocks: hypoadrenal, neurogenic, obstructive				

Type of shock

JVP
Central venous pressure
Pulmonary capillary pressure
Sign of hypovolemia

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic	↓	~↑	↑	Blood or fluid loss (internal, external)
Cardiogenic	↑	↓	↑	Warm vs. cold skin pale Systemic vascular resistant
Distributive	~↓	↑↓	↓	Septic, anaphylaxis, inflammation, toxin

Other type of shocks: hypoadrenal, neurogenic, obstructive

S&S symptoms of hypoperfusion

Δ mental status

Tachycardia

↓ BP

↓ urine

cold skin

↑Cr, ↑Lactic acid.

Treatment

Recognize shock

Reverse the cause(s)

- In a timely fashion

Support and prevent further end organ damage

- Restore perfusion

ICU:

Invasive monitor: Arterial line, foley cath, PA catheter (Swann-Ganz)

Ventilation support: O2 support, Mechanical Ventilator/ Endotracheal tube

Fluid resuscitation: Crystalloid > colloid. ~~Cardiogenic shock~~

Hemodynamic support: Inotrope, pressor, VAD

	Action	Usual dose	C ¹	A ²	Note
Epinephrine	$\alpha 1$ $\beta 1$ $\beta 2$	0.01-0.1mcg/kg/min 1 mg iv bolus q 3 mins	↑↑↑↑	↑↑↑	Low dose = more β . (like dobutamine) High dose = more α . (like norepi) Use: ACLS, anaphylaxis, S/E: splanchnic vasoconstrict.
Norepinephrine	$\alpha 1$ $\beta 1$ $\beta 2$	0.01-3 mcg/kg/min	↑↑↑	↑↑↑↑	Potent vasoconstriction. Moderate ↑CO. ~HR effect (reflex bradycardia from increased MAP). Use: Septic shock.
Dopamine Low Moderate High	DA $\alpha 1$ $\beta 1$ $\beta 2$ DA $\alpha 1$ $\beta 1$ $\beta 2$ DA	0.5 - 2 mcg/kg/min 2-10 mcg/kg/min 10-20 mcg/kg/min	~ ↑↑ ↑↑	↓ ↑ ↑↑↑	Precursor to norepi but less α , more β effect. Dose-dependent effects. Dose is varied pt to pt. Use: Septic shock, 2 nd -line alternative to norepinephrine.
Dobutamine	$\beta 1$ $\beta 2$ ($\alpha 1$)	2- 20 mcg/kg/min	↑↑	↓↓	Not a vasopressor. Inotrope with a vasodilation. The net effect = ↑CO + ↓SVR, may not ↓BP. Use: HF, cardiogenic.
Milrinone	PDE inh	0.375 – 0.75 mcg/kg/min	↑↑	↓↓↓	Similar to dobutamine more vasodilator, ↓PA Use: HF, cardiogenic.
Isoproterenol	$\beta 1$ $\beta 2$	2-10 mcg/min	↑	↓↓↓	Prominent chronotropic. Prominent vasodilation. Use: Bradycardia
Phenylephrine	$\alpha 1$	0.5-10 mcg/kg/min	0	↑↑↑	Pure vasoconstriction. May decrease SV.
Vasopressin	V ₁	0.04 unit/min	0	↑↑↑	Pure vasoconstriction. Use: 2 nd -line in refractory vasodilatory shock. S/E: coronary, mesenteric ischemia, skin necrosis. ↓Na and pulm vasoconstriction

Sample

A 55 yo M with hx of HTN, DM presents with “crushing” substernal CP, diaphoresis, hypotension, tachycardia and cool, clammy extremities

An 81 yo F from a nursing home presents to the ED with altered mental status. She is febrile to 39.4, hypotensive with a widened pulse pressure, tachycardic, with warm extremities

A 68 yo M with hx of HTN and DM presents to the ER with abrupt onset of diffuse abdominal pain with radiation to his low back. The pt is hypotensive, tachycardic, afebrile, with cool but dry skin

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

CRITICAL CARE MEDICINE

Simon R. Finfer, M.D., and Jean-Louis Vincent, M.D., Ph.D., Editors

Circulatory Shock

Jean-Louis Vincent, M.D., Ph.D., and Daniel De Backer, M.D., Ph.D.

N Engl J Med 2013; 369:1726-1734

Cause of Hypovolemic Shock

- Non-hemorrhagic
 - Vomiting
 - Diarrhea
 - Bowel obstruction, pancreatitis
 - Burns
 - Neglect, environmental (dehydration)
- Hemorrhagic
 - GI bleed
 - Trauma
 - Massive hemoptysis
 - AAA rupture
 - Ectopic pregnancy, post-partum bleeding

Cause of Septic shock

Another lecture by it self


Most common type of shock

Hypoperfusion + infection + 2 SIRS (systemic inflammatory response syndrome) criteria

- S&S of hyperperfusion

- Temp > 38 or < 36 C
- HR > 90
- RR > 20
- WBC > 12,000 or < 4,000

- Plus the presumed existence of infection




Cardiogenic shock



Hypoperfusion due to low cardiac output

- Low BP, high PCWP
- SBP < 90 mmHg
- CI < 2.2 L/m/m²
- PCWP > 18 mmHg

50% mortality rate



Heart failure




HF is a syndrome caused by cardiac dysfunction, generally resulting from myocardial muscle dysfunction or loss and characterized by either LV dilation or hypertrophy or both. Whether the dysfunction is primarily systolic or diastolic or mixed, it leads to neurohormonal and circulatory abnormalities, usually resulting in characteristic symptoms such as fluid retention, shortness of breath, and fatigue, especially on exertion. In the

spontaneously or as a consequence of therapy. In physiologic terms, HF is a syndrome characterized by either or both pulmonary and systemic venous congestion and/or inadequate peripheral oxygen delivery, at rest or during stress, caused by cardiac dysfunction.

Definition of HF

1. A syndrome caused by cardiac dysfunction
 2. Leads to circulatory abnormalities and neurohormonal abnormality
 3. Resulting in typical symptoms of
 - Congestion
 - Poor perfusion
- a. Common pathway from any causes
 b. Progressive, vicious cycle
 c. Systemic maladaptation



Cause of HF

Table of Contents

Preamble e242

1. Introduction e245

1.1. Methodology and Evidence Review e245

1.2. Organization of the Writing Committee e245

1.3. Document Review and Approval e245

1.4. Scope of This Guideline With Reference to Other Relevant Guidelines or Statements e245

2. Definition of HF e246

2.1. HF With Reduced EF (HFrEF) e247

2.2. HF With Preserved EF (HFpEF) e247

3. HF Classifications e247

4. Epidemiology e248

4.1. Mortality e248

4.2. Hospitalizations e248

4.3. Asymptomatic LV Dysfunction e248

4.4. Health-Related Quality of Life and Functional Status e249

4.5. Economic Burden of HF e249

4.6. Important Risk Factors for HF (Hypertension, Diabetes Mellitus, Metabolic Syndrome, and Atherosclerotic Disease) e249

5. Cardiac Structural Abnormalities and Other Causes of HF e249

5.1. Dilated Cardiomyopathies e249

5.1.1. Definition and Classification of Dilated Cardiomyopathies e249

5.1.2. Epidemiology and Natural History of DCM e250

5.2. Familial Cardiomyopathies e250

5.3. Endocrine and Metabolic Causes of Cardiomyopathy e250

5.3.1. Obesity e250

5.3.2. Diabetic Cardiomyopathy e250

5.3.3. Thyroid Disease e250

5.3.4. Acromegaly and Growth Hormone Deficiency e250

5.4. Toxic Cardiomyopathy e251

5.4.1. Alcoholic Cardiomyopathy e251

5.4.2. Cocaine Cardiomyopathy e251

5.4.3. Cardiotoxicity Related to Cancer Therapies e251

5.4.4. Other Myocardial Toxins and Nutritional Causes of Cardiomyopathy e251

5.5. Tachycardia-Induced Cardiomyopathy e251

5.6. Myocarditis and Cardiomyopathies Due to Inflammation e251

5.6.1. Myocarditis e251

5.6.2. Acquired Immunodeficiency Syndrome e252

5.6.3. Chagas Disease e252

5.7. Inflammation-Induced Cardiomyopathy: Noninfectious Causes e252

5.7.1. Hypersensitivity Myocarditis e252

5.7.2. Rheumatological/Connective Tissue Disorders e252

5.8. Peripartum Cardiomyopathy e252

5.9. Cardiomyopathy Caused by Iron Overload e252

5.10. Amyloidosis e252

5.11. Cardiac Sarcoidosis e253

5.12. Stress (Takotsubo) Cardiomyopathy e253

6. Initial and Serial Evaluation of the HF Patient e253

6.1. Clinical Evaluation e253

6.1.1. History and Physical Examination: Recommendations e253

6.1.2. Risk Scoring: Recommendation e253

6.2. Diagnostic Tests: Recommendations e253

6.3. Biomarkers: Recommendations e255

6.3.1. Natriuretic Peptides: BNP or NP-proBNP e256

6.3.2. Biomarkers of Myocardial Injury: Cardiac Troponin T or I e256

6.3.3. Other Emerging Biomarkers e256

6.4. Noninvasive Cardiac Imaging: Recommendations e256

6.5. Invasive Evaluation: Recommendations e258

6.5.1. Right-Heart Catheterization e259

6.5.2. Left-Heart Catheterization e259

6.5.3. Endomyocardial Biopsy e260

7. Treatment of Stages A to D e260

7.1. Stage A: Recommendations e260

7.1.1. Recognition and Treatment of Elevated Blood Pressure e260

7.1.2. Treatment of Dyslipidemia and Vascular Risk e260

7.1.3. Obesity and Diabetes Mellitus e260

7.1.4. Recognition and Control of Other Conditions That May Lead to HF e260


7.2. Stage B: Recommendations e261


7.2.1. Management Strategies for Stage B e262

7.3. Stage C e262


Circulation. 2013;128:e240-e327.


Pathophysiology





Renin-angiotensin-aldosterone system





J Am Coll Cardiol 2009;54:375–85.

TABLE 25-2 Overview of Left Ventricular Remodeling

Alterations in Myocyte Biology

- Excitation-contraction coupling
- Myosin heavy chain (fetal) gene expression
- Beta-adrenergic desensitization
- Hypertrophy
- Myocytolysis
- Cytoskeletal proteins


Myocardial Changes

- Myocyte loss
 - Necrosis
 - Apoptosis
 - Autophagy
- Alterations in extracellular matrix
 - Matrix degradation
 - Myocardial fibrosis

Alterations in Left Ventricular Chamber Geometry

- LV dilation
- Increased LV sphericity
- LV wall thinning
- Mitral valve incompetence

Stage of HF



S&S of HF

Non specific, fatigue

Dyspnea from increased breathing drive

- Reduction in exercise capacity (NYHA II-IV)
- Orthopnea, PND

Edema, ascites, early satiety, N/V, confusion

Apical shift, S3, S4, ↑ JVP, (+) HJ reflux, ascites, crepitation, edema



Treatment

Self-care

- weight monitor, ↓ salt intake

Diuretics to control symptoms

Treatment

To improve survival

- Betablocker
- ACE inhibitor or Angiotensin receptor blocker (ARB)
- Aldosterone blocker - spironolactone
- If channel inhibitor - Ivabradine
- Angiotensin receptor, neprilysin inhibitor (ARNI) - Valsartan/sacubitril
- Cardiac resynchronize therapy (special pacemaker)
- Implantable cardioverter Defibrillator

End-stage HF

- Heart transplant
- Mechanical circulatory support
- Inotrope
- Palliative care

Advances in Heart Failure

The “Modern” View of Heart Failure How Did We Get Here?

Arnold M. Katz, MD

Circ Heart Fail.2008;1:63-71

Thank you


Aekarach.a@chula.ac.th



Back up slide



Pressure volume Loop of the LV




- A: MV close
- B: AV open
- C: AV close
- D: MV open

Ees: end-systolic elastance (ESPVR: End systolic PV Relationship)

Ea: Arterial elastance

EDPVR: End diastolic PV Relationship



Investigation

Lab: shock

- Cr, AST/ALT, WBC, acidosis
- Troponin

ECG:

- MI: ST elevation, Q wave, TW inversion

CXR: pulmonary edema

Echocardiogram: function, etiology

Pulmonary catheter (Swan-Ganz):

- DDx type of shock, intracardiac pressure, CO

Coronary angiogram